Table 7: Summary of Study Characteristics: Model 1.
| Study, Design (N), Country |
Inclusion Criteria† |
Intervention Group | Setting | Control¶ | Outcomes# | Length of FU (Freq. of FU)** |
Study Quality |
||
|---|---|---|---|---|---|---|---|---|---|
| Care provider |
Types of Interventions Delivered | Method of Care Delivery |
|||||||
| MODEL OF CARE: 1. At least a registered nurse, registered dietician and physician (primary care and/or specialist) | |||||||||
|
California Medi-Cal Diabetes Study Group, 2004 (14) RCT (N = 335) USA |
T2DM (>1y duration), age ≥18 y, HbA1c ≥7.5% | RN, RD, E, PCP, CDE |
|
Clinic visits (Individual) | Community outpatient clinics (n=3) | Usual care (by PCP) | Primary: HbA1c | 36 months (every 6 months) | High |
|
Gaede, et al, 2001 (13) RCT (N = 149) Denmark |
T2DM, age 45-65y | RN, RD, MD |
|
Clinic visits (Individual & Group) | Hospital outpatient clinic | Usual care (by PCP) | †† HbA1c, total-and HDL-cholesterol, triglycerides, body weight, current smokers, daily dietary intake, exercise, use of glucose- or lipid-lowering drugs | Mean: 3.8 years (every 3 months) | Moderate |
|
Groeneveld, et al, 2001 (16) Cluster RCT N = 246 Netherlands |
T2DM, age <76y, treated by a PCP | dRN (CDE), RD, PCP |
|
Clinic visits (Individual) | Primary carepractices (n=15) | Usual care (by PCP) | †† HbA1c, FBG, lipids, BP, weight | 12 months (every 3 months) | Moderate |
|
Johansen, et al, 2007 (15) RCT N = 106 Norway |
T2DM, age 18-75 y, Caucasian, ≥ 1 CV risk factor | dRN, RD, D, Physio |
|
Clinic visits (Individual & Group) | Hospital outpatient clinic | Usual care (by PCP) | †† HbA1c; BP; FBG; total, HDL and LDL cholesterol; triglycerides; microalbumin-uria; leisure-time activity; HRQoL | 24 months (every 3 months) | High |
|
Maislos, et al, 2004 (12) Cluster RCT N = 82 Israel |
T2DM, poorly controlled HbA1c (≥10%) | dRN (CDE), RD, D |
|
Clinic visits (Individual) | Primary carepractices (n=2) | Usual care (by PCP, RN) | †† HbA1c, compliance in attending clinic | 6 months (as needed) | Low |
RCT, randomized controlled trial
BP, blood pressure; CV, cardiovascular; HbA1c, glycosylated hemoglobin; mo, months; PCP, primary care physician; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; y, years
NA, not available (contacted study author; data unavailable); NR, not reported
CDE, certified diabetic educator; D, diabetologist; dRN, diabetes specialist nurse; E, endocrinologist; HCP, health care professional; MD, physician (unspecified specialty); PCP, primary care physician; Pharm, pharmacist; Physio, physiotherapist; RD, registered dietician; RN, registered nurse
PCP, primary care physician
MD, physician; PCP, primary care physician; Pharm, pharmacist; RN, nurse
blood pressure; FBG, fasting blood glucose; HDL, high-density lipoprotein; HRQoL, health-related quality of life; LDL, low-density lipoprotein cholesterol
FU, follow-up
No specification of primary or secondary outcomes